Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of oral pharmaceutical composition for treating myocardial ischemia-reperfusion injury

A technology for reperfusion injury and myocardial ischemia, which is applied in the field of medicine and can solve the problems of energy metabolism disorder, the difficulty of drugs to play an ideal therapeutic effect, and the uncertainty.

Active Publication Date: 2018-09-04
德州市洛泰商贸有限公司
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] 2. Calcium overload and myocardial ischemia-reperfusion injury
[0008] 3. Energy metabolism disorder and myocardial ischemia-reperfusion injury
[0019] However, so far, there is still a lack of drugs that have an ideal therapeutic effect on myocardial ischemia-reperfusion injury, which is related to the complex and unclear mechanism, and it is difficult for drugs targeting a single target to exert an ideal therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of oral pharmaceutical composition for treating myocardial ischemia-reperfusion injury
  • A kind of oral pharmaceutical composition for treating myocardial ischemia-reperfusion injury
  • A kind of oral pharmaceutical composition for treating myocardial ischemia-reperfusion injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Granules for treating myocardial ischemia-reperfusion injury and its preparation

[0043]

[0044] Preparation:

[0045] A: Take hyperoside, disulfiram, primaquine and rorapitant and pass through 100-mesh sieve respectively, and mix well.

[0046] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0047] The amount is 2.2 times of the weight of hyperin; the amount of microcrystalline cellulose is 1.2 times of the weight of hyperin; the amount of crospovidone is 0.13 times of the weight of hyperin.

[0048] C: Mix the powder obtained in step A and step B evenly.

[0049] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of hyperin; the consumption of water is 32.5 times of the weight of povidone K30.

[0050] E: The liquid dispersion system obtained in step D is added to...

Embodiment 2

[0052] Example 2 Granules for treating myocardial ischemia-reperfusion injury and its preparation

[0053]

[0054] Preparation:

[0055] A: Take hyperoside, disulfiram, primaquine and rorapitant and pass through 100-mesh sieve respectively, and mix well.

[0056] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0057] The amount is 2.2 times of the weight of hyperin; the amount of microcrystalline cellulose is 1.2 times of the weight of hyperin; the amount of crospovidone is 0.13 times of the weight of hyperin.

[0058] C: Mix the powder obtained in step A and step B evenly.

[0059] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of hyperin; the consumption of water is 32.5 times of the weight of povidone K30.

[0060] E: The liquid dispersion system obtained in step D is added to...

Embodiment 3

[0062] Example 3 Granules for treating myocardial ischemia-reperfusion injury and its preparation

[0063]

[0064] Preparation:

[0065] A: Take hyperoside, disulfiram, primaquine and rorapitant and pass through 100-mesh sieve respectively, and mix well.

[0066] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0067] The amount is 2.2 times of the weight of hyperin; the amount of microcrystalline cellulose is 1.2 times of the weight of hyperin; the amount of crospovidone is 0.13 times of the weight of hyperin.

[0068] C: Mix the powder obtained in step A and step B evenly.

[0069] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of hyperin; the consumption of water is 32.5 times of the weight of povidone K30.

[0070] E: The liquid dispersion system obtained in step D is added to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of medicine, and particularly relates to an oral pharmaceutical composition for treating myocardial ischemia-reperfusion injury. The oral pharmaceutical compositionfor treating the myocardial ischemia-reperfusion injury is prepared from pharmaceutically acceptable pharmaceutical adjuvants and hyperin, disulfiram, primaquine and rolapitant, wherein the ratios ofthe hyperoside, the disulfiram, the primaquine and the rolapitant are, by weight, 180-300 parts of the hyperoside, 12-20 parts of the disulfiram, 3-9 parts of the primaquine and 2-5parts of the rolapitant. According to the composition, the rolapitant inhibits cardiovascular toxicity of the disulfiram and the primaquine, and eliminates efficacy counteracting phenomenon when the disulfiram and the primaquine are used in combination; the composition of the hyperin, the disulfiram, the primaquine and the rolapidtant has good resistance on the myocardial ischemia-reperfusion injury and safety.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an oral pharmaceutical composition for treating myocardial ischemia-reperfusion injury. Background technique [0002] Ischemia reperfusion injury (Ischemia reperfusion injury) is a phenomenon that when the body tissue ischemia and reperfusion, not only does not restore the function of tissues and organs, but further aggravates the functional metabolism and structural damage caused by ischemia. Ischemia-reperfusion injury can occur in various major organs involved in blood circulation, such as cerebral ischemia-reperfusion injury, cardiac ischemia-reperfusion injury, liver ischemia-reperfusion injury, etc. With the widespread use of coronary interventional surgery and thrombolysis, the incidence of myocardial ischemia-reperfusion injury will inevitably increase. Recanalization of blood flow after ischemia not only improves myocardial blood supply, but also aggravates the damag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61K31/145A61K31/4706A61K31/438A61K9/16A61P9/10A61P7/08
CPCA61K9/1652A61K31/145A61K31/438A61K31/4706A61K31/7048A61K2300/00
Inventor 侯瑞玲王金永姚蕾
Owner 德州市洛泰商贸有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com